Nemaura Medical (Nasdaq:NMRD) announced today that it now includes insulin under its DuoPack commercial license agreement. Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.” […]
Nemaura Medical
Nemaura Medical garners U.S.-based purchase order for glucose sensors
Nemaura Medical (Nasdaq:NMRD) announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions. HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on […]
Nemaura Medical dips on Q1 losses
Nemaura Medical (NSDQ:NMRD) shares took a slight hit today on first-quarter results that reflected losses of over $1 million. The Loughborough, England-based continuous glucose monitor maker did not report its revenue numbers for the quarter, having posted losses of $1.1 million, or -5¢ per share for the three months ended June 30, 2020, for a 12.1% […]
Nemaura Medical repurposes its CGM to spot coronavirus fevers
Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. The Loughborough, England-based company said in a news release that its inbuilt temperature sensor is capable of continuously tracking body temperature through the […]
Nemaura Medical enters non-binding agreements for its SugarBeat platform
Nemaura Medical (NSDQ:NMRD) announced today that it entered into multiple verbal non-binding agreements for its SugarBeat continuous glucose monitor as it seeks to secure regional and global partnerships. The Loughborough, U.K.–based company expects the agreements to lead to discussions over licensing and collaboration, but can’t guarantee that deals will be struck as planned, or at all, […]
Nemaura bids for de novo clearance from FDA for SugarBEAT glucose monitor
Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. “We are pleased to have submitted our De Novo 510(k) application […]
Nemaura Medical wins CE Mark for SugarBeat CGM
Nemaura Medical (NSDQ:NMRD) said yesterday that it won CE Mark approval for its SugarBEAT continuous glucose monitor. The SugarBEAT CGM is a flexible, disposable patch that’s connected to a rechargeable transmitter and Bluetooth-enabled smartphone app, designed to deliver glucose readings at five-minute intervals throughout the day. The company says the device allows users to spend more […]
Nemaura prices $2.5m offering to support launch of wearable glucose monitor
Nemaura Medical (NSDQ:NMRD) said this week that it priced a public offering of the company’s common stock and warrants, hoping to reel in $2.5 million in proceeds. The offering is slated to close today. Nemaura plans to use the offering’s proceeds to support the launch of its wearable glucose monitor in Europe, as well as the […]
Nemaura develops predictive algorithms for continuous glucose monitor
Nemaura Medical (NSDQ:NMRD) said today that it successfully developed predictive algorithms to support alarm functions in its sugarBeat continuous glucose monitoring system. The England-based company touted that its device’s alarm functionality can predict a user’s glucose level five minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with […]
Nemaura touts data from home-use study of wearable glucose monitor
Nemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S. The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device. The company’s interim results included findings from 25 patients with either Type […]
